Skip to main content
Top
Published in: Clinical Rheumatology 11/2012

01-11-2012 | Original Article

A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis

Authors: Fernando A. Sommerfleck, Emilce E. Schneeberger, Emilio E. Buschiazzo, José A. Maldonado Cocco, Gustavo Citera

Published in: Clinical Rheumatology | Issue 11/2012

Login to get access

Abstract

This study aimed to develop a simplified version of the Ankylosing Spondylitis Disease Activity Score (ASDAS). The study included consecutive patients with ankylosing spondylitis according to modified New York and/or Assessment in Ankylosing Spondylitis 2009 criteria. Sociodemographic data and characteristics of the disease (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and Ankylosing Spondylitis Quality of Life (ASQoL)) and erythrocyte sedimentation rate (ESR) were collected. ASDAS simplified version (SASDAS) was calculated as the simple linear sum of the five components of ASDAS which include: patient global assessment using visual analogue scale, back pain (BASDAI question no. 2), peripheral pain and swelling (BASDAI question no. 3), morning stiffness (BASDAI question no. 6), and ESR in millimeters per hour, divided by 10 so as to make it equivalent to the other scale's components. Eighty-six patients were included: 69 (80.2 %) were men with a median age of 46 years and median disease duration of 19 years. SASDAS showed an excellent correlation with the ASDAS (r = 0.93). SASDAS also showed a good correlation with night pain (r = 0.60), global pain (r = 0.69), ASQoL (r = 0.70), BASFI (r = 0.75), and BASDAI (r = 0.96). Using ASDAS cut-off values previously suggested, the corresponding cut-off values for SASDAS were as follows: from 0 to 7.8 (inactive disease), from 7.9 to 13.8 (moderate disease activity), from 13.9 to 27.6 (high disease activity), and above 27.6 (very high disease activity) with optimum sensitivity and specificity. SASDAS showed an excellent correlation with conventional clinical measures of disease activity, and it can be easily calculated and is simple to use in daily clinical practice.
Literature
1.
go back to reference González-Roces S, Alvarez V (1996) HLA-B27 structure, function, and disease association. Curr Opin Rheumatol 8(4):296–308PubMedCrossRef González-Roces S, Alvarez V (1996) HLA-B27 structure, function, and disease association. Curr Opin Rheumatol 8(4):296–308PubMedCrossRef
2.
go back to reference Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 24:908–911 Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 24:908–911
3.
go back to reference van der Linden S, van der Heijde D (1998) Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am 24:663–673PubMedCrossRef van der Linden S, van der Heijde D (1998) Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am 24:663–673PubMedCrossRef
4.
go back to reference Hammer RE, Maika SD, Richardson JA (1990) Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 63(5):1099–1112PubMedCrossRef Hammer RE, Maika SD, Richardson JA (1990) Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 63(5):1099–1112PubMedCrossRef
5.
go back to reference Dalyan M, Guner A, Tuncer S, BilgiÇ A, Arasil T (1999) Disability in ankylosing spondylitis. Disabil Rehabil 21:74–79PubMedCrossRef Dalyan M, Guner A, Tuncer S, BilgiÇ A, Arasil T (1999) Disability in ankylosing spondylitis. Disabil Rehabil 21:74–79PubMedCrossRef
6.
go back to reference Masi AT, Walsh EG (2003) Ankylosing spondylitis: integrated clinical and physiological perspectives. Clin Exp Rheumatol 21:1–8PubMed Masi AT, Walsh EG (2003) Ankylosing spondylitis: integrated clinical and physiological perspectives. Clin Exp Rheumatol 21:1–8PubMed
7.
go back to reference Marengo MF, Schneeberger EE, Citera G, Maldonado Cocco JA (2008) Work status among patients with ankylosing spondylitis in Argentina. J Clin Rheumatol 14:273–277PubMedCrossRef Marengo MF, Schneeberger EE, Citera G, Maldonado Cocco JA (2008) Work status among patients with ankylosing spondylitis in Argentina. J Clin Rheumatol 14:273–277PubMedCrossRef
8.
go back to reference Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed
9.
go back to reference Lukas C, Landewé R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patient with ankylosing spondylitis. Ann Rheum Dis 68:18–24PubMedCrossRef Lukas C, Landewé R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patient with ankylosing spondylitis. Ann Rheum Dis 68:18–24PubMedCrossRef
10.
go back to reference Pedersen SJ, Sorensen IJ, Hermann KG et al (2010) Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 69:1065–1071PubMedCrossRef Pedersen SJ, Sorensen IJ, Hermann KG et al (2010) Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 69:1065–1071PubMedCrossRef
11.
go back to reference Nas K, Yildirim K, Cevik R et al (2010) Discrimination ability of ASDAS estimating disease activity status in patient with ankylosing spondylitis. Inter J Rheum Dis 13:240–245CrossRef Nas K, Yildirim K, Cevik R et al (2010) Discrimination ability of ASDAS estimating disease activity status in patient with ankylosing spondylitis. Inter J Rheum Dis 13:240–245CrossRef
12.
go back to reference Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42:244–257PubMedCrossRef Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42:244–257PubMedCrossRef
13.
go back to reference Machado P, Landewé R, Lie E et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70:47–53PubMedCrossRef Machado P, Landewé R, Lie E et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70:47–53PubMedCrossRef
14.
go back to reference van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for the modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for the modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef
15.
go back to reference Sieper J, van der Heijde D, Landewé R et al (2009) New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of Spondyloarthritis international Society (ASAS). Ann Rheum Dis 68:784–788PubMedCrossRef Sieper J, van der Heijde D, Landewé R et al (2009) New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of Spondyloarthritis international Society (ASAS). Ann Rheum Dis 68:784–788PubMedCrossRef
16.
go back to reference Doward L, Spoorerg A, Cook S et al (2003) Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20–26PubMedCrossRef Doward L, Spoorerg A, Cook S et al (2003) Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20–26PubMedCrossRef
17.
go back to reference Calin A, Garrett SL, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to functional ability in ankylosing spondylitis: the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed Calin A, Garrett SL, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to functional ability in ankylosing spondylitis: the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed
18.
go back to reference Citera G, Maldonado Cocco J, Moroldo M, Burgos-Vargas R, Anaya J, López I, Gutiérrez M (1999) Validación de la versión en español de los cuestionarios de capacidad funcional (BASFI) y actividad de la enfermedad (BASDAI) en pacientes con Espondilitis Anquilosante en cuatro países latinoamericanos. Rev Argent Reumatol 10(Supl 1):25 [abstract] Citera G, Maldonado Cocco J, Moroldo M, Burgos-Vargas R, Anaya J, López I, Gutiérrez M (1999) Validación de la versión en español de los cuestionarios de capacidad funcional (BASFI) y actividad de la enfermedad (BASDAI) en pacientes con Espondilitis Anquilosante en cuatro países latinoamericanos. Rev Argent Reumatol 10(Supl 1):25 [abstract]
19.
go back to reference Buschiazzo E, Sommerfleck F, Schneeberger EE, Arturi P, Maldonado Cocco JA, Citera G (2010) Validación del índice ASDAS en una cohorte de pacientes con Espondilitis Anquilosante. Rev Arg Reumatol 21:28 Buschiazzo E, Sommerfleck F, Schneeberger EE, Arturi P, Maldonado Cocco JA, Citera G (2010) Validación del índice ASDAS en una cohorte de pacientes con Espondilitis Anquilosante. Rev Arg Reumatol 21:28
20.
go back to reference Aydin SZ, Can M, Atagunduz P et al (2010) Active disease requiring TNF-alpha antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol 28:752–755PubMed Aydin SZ, Can M, Atagunduz P et al (2010) Active disease requiring TNF-alpha antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol 28:752–755PubMed
21.
go back to reference Eder L, Chandran V, Shen H et al (2010) Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 69:2160–2164PubMedCrossRef Eder L, Chandran V, Shen H et al (2010) Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 69:2160–2164PubMedCrossRef
22.
go back to reference Machado P, van der Heijde D (2011) How to measure disease activity in axial spondyloarthritis? Curr Opin Rheumatol 23:339–345PubMedCrossRef Machado P, van der Heijde D (2011) How to measure disease activity in axial spondyloarthritis? Curr Opin Rheumatol 23:339–345PubMedCrossRef
23.
go back to reference Curet AV, Rillo OL, Chaparro del Moral RE, Papasidero SB, Citera G, Maldonado Cocco JA et al (2005) Modificación y aplicación de un índice de actividad simplificado (IAS) en pacientes con Artritis Reumatoidea. Rev Argent Reumatol Suppl 1:13 Curet AV, Rillo OL, Chaparro del Moral RE, Papasidero SB, Citera G, Maldonado Cocco JA et al (2005) Modificación y aplicación de un índice de actividad simplificado (IAS) en pacientes con Artritis Reumatoidea. Rev Argent Reumatol Suppl 1:13
24.
go back to reference Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:100–108 Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:100–108
Metadata
Title
A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis
Authors
Fernando A. Sommerfleck
Emilce E. Schneeberger
Emilio E. Buschiazzo
José A. Maldonado Cocco
Gustavo Citera
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 11/2012
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-012-2056-7

Other articles of this Issue 11/2012

Clinical Rheumatology 11/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.